Making Medicine

Incubate Coalition
  • 5.0 (15)
  • HEALTH & FITNESS
  • UPDATED SEMIWEEKLY
Making Medicine

There's a scientific breakthrough in your medicine cabinet. But how did it get there? At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients. From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures. In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.

  1. APR 18

    When Progress Gets Penalized: Biotech in the Age of IRA

    The path to new medicines is complex enough - policy doesn’t need to make it more difficult. But it does.  In this episode, Thomas Kaiser, Co-Founder and Chief Scientific Officer Avicenna Biosciences joins the show to share how the Inflation Reduction Act is unintentionally discouraging investment in small-molecule drugs, creating the pill penalty. He explains why this matters not just to biotech founders, but to millions of patients waiting for treatments for conditions like Parkinson’s, MS, and diabetes.  We also discuss: What’s at risk when chronic disease treatments are deprioritized due to poor incentivesWhy policymakers often misunderstand biotech timelines and how that disconnect can block life-saving innovation.How North Carolina’s foresight turned it into a biotech innovation hub.Read Tom’s Op-ed in BioSpace.

    23 min

  2. FEB 13

    Bridging Science and Business: A Conversation with Professor Fred Ledley

    In this episode of The Making Medicine podcast, John Stanford sits down with Professor Fred Ledley, Director of the Center for Integration of Science and Industry at Bentley University. Professor Ledley shares his journey from medical school to biotech entrepreneurship and academia, highlighting the critical intersection of science and business. The discussion explores the evolution of gene therapy, personalized medicine, and the role of industry in driving medical innovation. Key Takeaways:The integration of science and business is essential for advancing healthcare innovations.Gene therapy and personalized medicine have evolved significantly, shaping modern treatments.Collaboration between researchers, entrepreneurs, and policymakers accelerates medical progress.

    43 min

  3. 10/15/2024

    Can We Fix Healthcare? A Look Inside Our System

    The U.S. healthcare system is a puzzle for many. To fix it, we need smarter discussions and a deeper understanding of both the industry and the policies that shape it. In this episode, host John Stanford talks to healthcare policy expert Brian Reid, Principal at Reid Strategic and author of the Cost Curve newsletter, to discuss the challenges of fixing the incentives that have led to a broken healthcare system. We also discuss:How the healthcare debate often overlooks the needs of patients, focusing instead on assigning blame to various system stakeholders.The potential consequences price controls could have on pharmaceutical innovation (particularly for small molecules and cancer treatments).Why the current healthcare environment discourages companies from investing in long-term R&D, particularly in drug types that primarily benefit the elderly.

    19 min

  4. 09/13/2024

    Protecting Innovation: Small Molecules and the Future of Medicine

    Science should lead our policy decisions—not the other way around.  In this episode, Kirsten Axelson, Senior Policy Lab Advisor at Incubate Coalition, dives deep into the power of small molecule medicines, the promise they hold for the future, and how our current policy landscape may upend their development.   This conversation focuses on Incubate Policy Lab’s most recent white paper, which sheds light on the crucial role these molecules play not only in innovative drug development, but also in ensuring equitable access to life-saving treatments.  Listeners will learn: ​​The crucial role small molecules play in modern medicine, especially in treating conditions like cancer and neurological diseases.How current policy decisions, such as those in the Inflation Reduction Act, could negatively affect the development and accessibility of small molecule drugs.Why small molecule medicines contribute to equitable access to healthcare, especially for underserved populations and in global health contexts. To learn more about Kirsten’s white paper, please go to incubatecoalition.org

    18 min

  5. 06/28/2024

    CEO Series Part 1: Sherine Chan, CEO & Co-founder of Neuroene Therapeutics

    As part of our inaugural CEO series, we're excited to welcome Sherine Chan, the CEO and Co-Founder of Neuroene Therapeutics. In this episode, Sherine shares her journey from academia to helming a cutting-edge biotech company. She explores the groundbreaking work her company is pioneering in targeting the powerhouses of cells: mitochondria. Sherine also dives into the influence of the Inflation Reduction Act on the development of small-molecule drugs We also discuss: Neuroene Therapeutics' ongoing projects.The critical role of mitochondrial dysfunction in neurological conditions such as epilepsy, Parkinson's, and mitochondrial disorders.Sherine's insights for aspiring entrepreneurs and scientists.

    17 min

  6. 05/03/2024

    Dispelling Misconceptions in Biopharmaceutical IP Regulation

    On World IP Day, Kirsten Axelsen, Senior Advisor of the Incubate Policy Lab, joins host John Stanford to announce the newest whitepaper, delve into the myths and realities surrounding IP in the pharmaceutical industry, explore the dynamics of patent regulations, and touch on the contentious discussions around patent thickets and pharmaceutical pricing under new legislative environments like the Inflation Reduction Act. Join us as we also discuss: What to expect out of the Incubate Policy LabThe role that venture investment plays in advancing promising science and technology.The latest whitepaper that addresses misconceptions about IPThe implications of IRA policies in weakening the generics industry, potentially disrupting the balance that has historically led to affordable drug pricing post-patent expiration.

    25 min

  7. 04/11/2024

    When the Feds Come Marching In: A Deep Dive on The Bayh-Dole Act

    Joe Allen, Executive Director of The Bayh-Dole Coalition, was at the forefront of the Bayh-Dole Act back in December 1980, which allowed researchers to own inventions resulting from federally funded research. However, 43 years later, the March-In Rights framework proposed by the Biden administration threatens to weaken America’s innovation. In this episode, Joe delves into the potential implications of this framework on drug pricing, the pipeline, and overall innovation. Join us as we discuss: The significance of the Bayh-Dole Act and intellectual property in transforming how America drives innovation.Why public-private partnerships and collaboration in the medical field are key for funding research projects.The implications of enacting March-In Rights on the drug development pipeline

    22 min

  8. 09/13/2023

    Beyond Medicine: Solving Disparities in Cancer Care

    How can we create better outcomes for cancer patients? That’s the big goal Mohit Manrao is aiming for in his work as SVP & Head of US Oncology at AstraZeneca. In this episode, Mohit shares his perspective on the future of oncology and the pursuit of patient-centric care in a post-Inflation Reduction Act world. Join us as we discuss: AstraZeneca's goal of launching 15 new drugs by 2030Solving for disparities in care and improving health equityTimeline for drug development and its effect on patient outcomes

    25 min
See All (32)

Trailer

Ratings & Reviews

5
out of 5
15 Ratings

About

There's a scientific breakthrough in your medicine cabinet. But how did it get there? At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients. From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures. In this golden age of health discovery and innovation fueled by record breaking investment in the life sciences, we'll bring guests who really understand what it means to be Making Medicine.

Information

  • Creator
    Incubate Coalition
  • Years Active
    2021 - 2025
  • Episodes
    32
  • Rating
    Clean
  • Copyright
    © Copyright Sweet Fish
  • Show Website
    Making Medicine

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada